Search

Your search keyword '"Koranteng, Paul"' showing total 19 results
Start Over Author "Koranteng, Paul"
19 results on '"Koranteng, Paul"'

1. Dysfunctional cerebral glucose transport in Alzheimer’s Disease

Author

Nowell, Joseph, primary, Femminella, Grazia Daniela, additional, Ritchie, Craig W, additional, Holmes, Clive, additional, Walker, Zuzana, additional, Ridha, Basil H, additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Benjamin, additional, Koranteng, Paul, additional, Karim, Salman, additional, Prasanna, Aparna, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Nilforooshan, Ramin, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Holscher, Christian, additional, Harrison, John E, additional, Hinz, Rainer, additional, Tadros, George, additional, Passmore, Anthony Peter, additional, Ballard, Clive G, additional, and Edison, Paul, additional

Published
2023
Full Text
View/download PDF

2. MRI CHANGES FOLLOWING TREATMENT OF GLP‐1 ANALOGUE, LIRAGLUTIDE IN ALZHEIMER’S DISEASE

Author

Edison, Paul, primary, Femminella, Grazia Daniela, additional, Ritchie, Craig, additional, Nowell, Joseph, additional, Holmes, Clive, additional, Walker, Zuzana, additional, Ridha, Basil H, additional, Williams, Gareth, additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Benjamin, additional, Koranteng, Paul, additional, Karim, Salman, additional, Perneczky, Robert, additional, Prasanna, Aparna, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Nilforooshan, Ramin, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Holscher, Christian, additional, Mansouri, Anita, additional, Chester‐Jones, Mae, additional, Holmes, Jane, additional, Harrison, John E, additional, Tadros, George, additional, Passmore, Anthony Peter, additional, and Ballard, Clive G, additional

Published
2023
Full Text
View/download PDF

3. Magnetic Resonance Spectroscopy metabolites as biomarkers of Alzheimer’s Disease

Author

Nowell, Joseph, primary, Young, Megan, additional, Femminella, Grazia Daniela, additional, Ritchie, Craig W, additional, Holmes, Clive, additional, Walker, Zuzana, additional, Ridha, Basil H, additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Benjamin, additional, Koranteng, Paul, additional, Karim, Salman, additional, Prasanna, Aparna, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Nilforooshan, Ramin, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Holscher, Christian, additional, Harrison, John E, additional, Hinz, Rainer, additional, Tadros, George, additional, Passmore, Anthony Peter, additional, Ballard, Clive G, additional, and Edison, Paul, additional

Published
2023
Full Text
View/download PDF

4. Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?

Author

Femminella, Grazia Daniela, Livingston, Nicholas R., Raza, Sanara, van der Doef, Thalia, Frangou, Eleni, Love, Sharon, Busza, Gail, Calsolaro, Valeria, Carver, Stefan, Holmes, Clive, Ritchie, Craig W., Lawrence, Robert M., McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben, Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Passmore, Anthony Peter, Nilforooshan, Ramin, Macharouthu, Ajayverma, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Tan, Tricia, Holscher, Christian, Harrison, John, Brooks, David J., Ballard, Clive, and Edison, Paul

Published
2021
Full Text
View/download PDF

5. Correction to: Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Author

Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Hölscher, Christian, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, and Edison, Paul

Published
2020
Full Text
View/download PDF

6. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer’s disease: study protocol for a randomised controlled trial (ELAD study)

Author

Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, and Edison, Paul

Published
2019
Full Text
View/download PDF

7. Additional file 2 of Does insulin resistance influence neurodegeneration in non-diabetic Alzheimer’s subjects?

Author

Femminella, Grazia Daniela, Livingston, Nicholas R., Sanara Raza, Doef, Thalia Van Der, Frangou, Eleni, Love, Sharon, Busza, Gail, Calsolaro, Valeria, Carver, Stefan, Holmes, Clive, Ritchie, Craig W., Lawrence, Robert M., McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben, Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Kehinde Junaid, McGuinness, Bernadette, Passmore, Anthony Peter, Nilforooshan, Ramin, Ajayverma Macharouthu, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Naghma Malik, Mate, Vandana, Knight, Lucy, Sajeev Kshemendran, Tan, Tricia, Holscher, Christian, Harrison, John, Brooks, David J., Ballard, Clive, and Edison, Paul

Abstract

Additional file 2:. Table S1. Inclusion and exclusion criteria.

Published
2021
Full Text
View/download PDF

8. Correction to:Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease: Study protocol for a randomised controlled trial (ELAD study) (Trials. (2019) 20 (191) DOI: 10.1186/s13063-019-3259-x)

Author

Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Hölscher, Christian, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, and Edison, Paul

Abstract

After publication of our article [1] the authors have notified us that the name of Prof. Christian Hölscher had been inadvertently forgotten when compiling the list of authors. Dr. Hölscher developed the concept of testing liraglutide in Alzheimer’s mouse model, has done the preclinical experiments, and is a co-applicant of the Alzheimer ociety UK grant that partially funds the study.

Published
2020
Full Text
View/download PDF

9. Influence of cerebral glucose metabolic rate on cognitive function in Alzheimer's subjects

Author

Edison, Paul, primary, Femminella, Grazia Daniela, additional, Livingston, Nicholas R, additional, Raza, Sanara, additional, Nowell, Joseph, additional, Carver, Stefan, additional, Holmes, Clive, additional, Blunt, Eleanor G, additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Tadros, George, additional, Ritchie, Craig W, additional, Ridha, Basil H, additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John E, additional, Brooks, David J, additional, Passmore, Anthony Peter, additional, and Ballard, Clive, additional

Published
2020
Full Text
View/download PDF

10. Assessing the relationship between cognitive dysfunction and brain atrophy in Alzheimer's disease

Author

Edison, Paul, primary, Femminella, Grazia Daniela, additional, Nowell, Joseph, additional, Raza, Sanara, additional, Livingston, Nicholas R, additional, Blunt, Eleanor G, additional, Carver, Stefan, additional, Holmes, Clive, additional, Ritchie, Craig W, additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Tadros, George, additional, Ridha, Basil H, additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John E, additional, Brooks, David J, additional, Passmore, Anthony Peter, additional, and Ballard, Clive, additional

Published
2020
Full Text
View/download PDF

11. Relationship between spectral analysis, SUV and SUV Pons ratio as a measure of cerebral glucose metabolic rate in Alzheimer's disease

Author

Edison, Paul, primary, Raza, Sanara, additional, Femminella, Grazia Daniela, additional, Blunt, Eleanor G, additional, Carver, Stefan, additional, Livingston, Nicholas R, additional, Nowell, Joseph, additional, Holmes, Clive, additional, Ritchie, Craig W., additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Tadros, George, additional, Ridha, Basil H, additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John E, additional, Brooks, David J, additional, Passmore, Anthony Peter, additional, and Ballard, Clive, additional

Published
2020
Full Text
View/download PDF

12. Behavioural symptoms in Alzheimer’s disease are associated with white matter lesions (WML) volume and are independent of atrophy and hypometabolism

Author

Femminella, Grazia Daniela, primary, van der Doef, Thalia, additional, Carver, Stefan, additional, Holmes, Clive, additional, Ritchie, Craig W., additional, Lawrence, Robert M, additional, McFarlane, Brady, additional, Tadros, George, additional, Ridha, Basil H, additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Passmore, Anthony Peter, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John E., additional, Ballard, Clive, additional, Brooks, David J., additional, and Edison, Paul, additional

Published
2020
Full Text
View/download PDF

13. Additional file 1: of Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimerâ s disease: study protocol for a randomised controlled trial (ELAD study)

Author

Femminella, Grazia, Frangou, Eleni, Love, Sharon, Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil, Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben, Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Kehinde Junaid, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Naghma Malik, Mate, Vandana, Knight, Lucy, Sajeev Kshemendran, Harrison, John, Brooks, David, Passmore, Anthony, Ballard, Clive, and Edison, Paul

Abstract

SPIRIT 2013 checklist: items addressed in the clinical trial protocol. (DOC 121 kb)

Published
2019
Full Text
View/download PDF

14. Evaluating the effects of the novel GLP-1 analogue liraglutide in Alzheimer's disease:Study protocol for a randomised controlled trial (ELAD study)

Author

Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, Edison, Paul, Femminella, Grazia Daniela, Frangou, Eleni, Love, Sharon B., Busza, Gail, Holmes, Clive, Ritchie, Craig, Lawrence, Robert, McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben R., Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Nilforooshan, Ramin, Macharouthu, Ajay, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Brooks, David J., Passmore, Anthony Peter, Ballard, Clive, and Edison, Paul

Abstract

Background: Liraglutide is a glucagon-like peptide-1 (GLP-1) analogue currently approved for type 2 diabetes and obesity. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. The primary objective of the study is to evaluate the change in cerebral glucose metabolic rate after 12 months of treatment with liraglutide in participants with Alzheimer's disease compared to those who are receiving placebo. Methods/design: ELAD is a 12-month, multi-centre, randomised, double-blind, placebo-controlled, phase IIb trial of liraglutide in participants with mild Alzheimer's dementia. A total of 206 participants will be randomised to receive either liraglutide or placebo as a daily injection for a year. The primary outcome will be the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to follow-up in the treatment group compared with the placebo group. The key secondary outcomes are the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale - Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study - Activities of Daily Living) and the incidence and severity of treatment-emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes are 12-month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, reduction in microglial activation in a subgroup of participants, reduction in tau formation and change in amyloid levels in a subgroup of participants measured by tau and amyloid imaging, and changes in composite scores using support ma

Published
2019

15. P2-358: INSULIN RESISTANCE INFLUENCES HIPPOCAMPAL GLUCOSE METABOLISM RATHER THAN HIPPOCAMPAL VOLUME IN NON-DIABETIC ALZHEIMER'S DISEASE PATIENTS

Author

Femminella, Grazia Daniela, primary, van der Doef, Thalia, additional, Wang, Yi-Ting, additional, Frangou, Eleni, additional, Love, Sharon, additional, Calsolaro, Valeria, additional, Carver, Stefan, additional, Holmes, Clive, additional, Ritchie, Craig W., additional, Lawrence, Robert M., additional, McFarlane, Brady, additional, Tadros, George, additional, Ridha, Basil H., additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Passmore, Anthony Peter, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John, additional, Ballard, Clive, additional, Brooks, David J., additional, and Edison, Paul, additional

Published
2019
Full Text
View/download PDF

16. P3-328: DOES INSULIN RESISTANCE INFLUENCE WHITE MATTER LESIONS IN NON-DIABETIC AD SUBJECTS?

Author

Femminella, Grazia Daniela, primary, Wang, Yi-Ting, additional, van der Doef, Thalia, additional, Frangou, Eleni, additional, Love, Sharon, additional, Calsolaro, Valeria, additional, Carver, Stefan, additional, Holmes, Clive, additional, Ritchie, Craig W., additional, Lawrence, Robert M., additional, McFarlane, Brady, additional, Tadros, George, additional, Ridha, Basil H., additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Passmore, Anthony Peter, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John, additional, Ballard, Clive, additional, Brooks, David J., additional, and Edison, Paul, additional

Published
2019
Full Text
View/download PDF

17. Evaluation of liraglutide in the treatment of Alzheimer's disease.

Author

Edison, Paul, Femminella, Grazia Daniela, Ritchie, Craig W., Holmes, Clive, Walker, Zuzana, Ridha, Basil H, Raza, Sanara, Livingston, Nicholas R, Nowell, Joseph, Busza, Gail, Frangou, Eleni, Love, Sharon, Williams, Gareth, Lawrence, Robert M, McFarlane, Brady, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben, Koranteng, Paul, and Karim, Salman

Abstract

Background: Liraglutide is a glucagon‐like peptide‐1 (GLP‐1) analogue licensed for the treatment of type 2 diabetes. Preclinical evidence in transgenic models of Alzheimer's disease suggests that liraglutide exerts neuroprotective effects by reducing amyloid oligomers, normalising synaptic plasticity and cerebral glucose uptake, and increasing the proliferation of neuronal progenitor cells. Methods: ELAD is a 12‐month, multi‐centre, randomised, double‐blind, placebo‐controlled, phase IIb trial of liraglutide in participants with mild to moderate Alzheimer's dementia, conducted at several centres in the UK – (NCT01843075). [18F]FDG‐PET and MRI brain scans of all patients will be performed at baseline and after 12 months treatment with liraglutide or matching placebo. Once enrolled, all subjects had a neuropsychological battery of tests All scans and tests will be repeated after 12 months. A total of 204 participants were randomised to receive either liraglutide or placebo as a daily subcutaneous injection for 12 months. The primary objective was to evaluate the change in cerebral glucose metabolic rate in the cortical regions (hippocampus, medial temporal lobe, and posterior cingulate) from baseline to 12‐month follow‐up in participants with Alzheimer's disease receiving treatment with liraglutide compared to those receiving placebo. The key secondary outcomes were the change from baseline to 12 months in z scores for clinical and cognitive measures (Alzheimer's Disease Assessment Scale – Cognitive Subscale and Executive domain scores of the Neuropsychological Test Battery, Clinical Dementia Rating Sum of Boxes, and Alzheimer's Disease Cooperative Study – Activities of Daily Living) and the incidence and severity of treatment‐emergent adverse events or clinically important changes in safety assessments. Other secondary outcomes were 12‐month change in magnetic resonance imaging volume, diffusion tensor imaging parameters, and changes in composite scores using support machine vector analysis in the treatment group compared with the placebo group. Results: The study demonstrated that liraglutide treated patients performed significantly better than placebo arm in temporal lobe and whole cortical MRI volume and cognitive function measured by ADAS‐EXEC (ADAS‐Cog with Executive domains of the Neuropsychological Test Battery). Conclusion: This demonstrates that GLP1 analogues can improve cognitive function and MRI volume in AD subjects and could be a potential treatment for treatment for Alzheimer's [ABSTRACT FROM AUTHOR]

Published
2021
Full Text
View/download PDF

18. P3‐225: PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON‐DIABETIC ALZHEIMER'S PATIENTS

Author

Femminella, Grazia Daniela, primary, Fan, Zhen, additional, Frangou, Eleni, additional, Love, Sharon, additional, Calsolaro, Valeria, additional, Holmes, Clive, additional, Ritchie, Craig W., additional, Lawrence, Robert M., additional, McFarlane, Brady, additional, Tadros, George, additional, Ridha, Basil H., additional, Bannister, Carol, additional, Walker, Zuzana, additional, Archer, Hilary, additional, Coulthard, Elizabeth, additional, Underwood, Ben, additional, Prasanna, Aparna, additional, Koranteng, Paul, additional, Karim, Salman, additional, Junaid, Kehinde, additional, McGuinness, Bernadette, additional, Passmore, Anthony Peter, additional, Nilforooshan, Ramin, additional, Macharouthu, Ajayverma, additional, Donaldson, Andrew, additional, Thacker, Simon, additional, Russell, Gregor, additional, Malik, Naghma, additional, Mate, Vandana, additional, Knight, Lucy, additional, Kshemendran, Sajeev, additional, Harrison, John, additional, Ballard, Clive, additional, Brooks, David J., additional, and Edison, Paul, additional

Published
2018
Full Text
View/download PDF

19. PERIPHERAL INSULIN RESISTANCE DOES NOT CORRELATE WITH CEREBRAL GLUCOSE METABOLIC RATE IN NON-DIABETIC ALZHEIMER’S PATIENTS

Author

Femminella, Grazia Daniela, Fan, Zhen, Frangou, Eleni, Love, Sharon, Calsolaro, Valeria, Holmes, Clive, Ritchie, Craig W., Lawrence, Robert M., McFarlane, Brady, Tadros, George, Ridha, Basil H., Bannister, Carol, Walker, Zuzana, Archer, Hilary, Coulthard, Elizabeth, Underwood, Ben, Prasanna, Aparna, Koranteng, Paul, Karim, Salman, Junaid, Kehinde, McGuinness, Bernadette, Passmore, Anthony Peter, Nilforooshan, Ramin, Macharouthu, Ajayverma, Donaldson, Andrew, Thacker, Simon, Russell, Gregor, Malik, Naghma, Mate, Vandana, Knight, Lucy, Kshemendran, Sajeev, Harrison, John, Ballard, Clive, Brooks, David J., and Edison, Paul

Published
2018
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results